Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge

Journal of Clinical Investigation

Volumn 125, Issue 4, 2015, Pages 1637-1647

  Schickli, Jeanne H ^a   Whitacre, David C ^b   Tang, Roderick S ^a   Kaur, Jasmine ^a   Lawlor, Heather ^a   Peters, Cory J ^b   Jones, Joyce E ^b   Peterson, Darrell L ^c   McCarthy, Michael P ^a   Van Nest, Gary ^a   Milich, David R ^b  

^a MEDIMMUNE   (United States)

^b VLP Biotech Inc   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HEPATITIS B CORE ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN RECEPTOR; NEUTRALIZING ANTIBODY; PALIVIZUMAB; PLACEBO; RESTRICTION ENDONUCLEASE; F PROTEIN, HUMAN RESPIRATORY SYNCYTIAL VIRUS; HELIX LOOP HELIX PROTEIN; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS FUSION PROTEIN; VIRUS LIKE PARTICLE VACCINE; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IC50; IMMUNE RESPONSE; IMMUNOGENICITY; LACTOSE OPERON; MOUSE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; RESTRICTION SITE; T LYMPHOCYTE; VIRUS LIKE AGENT; WOODCHUCK HEPADNAVIRUS CORE BASED VIRUS LIKE PARTICLE; WOODCHUCK HEPATITIS VIRUS; ANIMAL; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; BIOSYNTHESIS; CHEMISTRY; COMBINATORIAL CHEMISTRY; CRYOELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; PROTEIN CONFORMATION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SIGMODONTINAE; VACCINATION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; ANTIGENS, VIRAL; COMBINATORIAL CHEMISTRY TECHNIQUES; CRYOELECTRON MICROSCOPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HELIX-LOOP-HELIX MOTIFS; HEPATITIS B VIRUS, WOODCHUCK; HUMANS; IMMUNODOMINANT EPITOPES; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; PALIVIZUMAB; PROTEIN CONFORMATION; RECOMBINANT FUSION PROTEINS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; SIGMODONTINAE; VACCINATION; VACCINES, VIRUS-LIKE PARTICLE; VIRAL FUSION PROTEINS; VIRAL VACCINES;

EID: 84926322660     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI78450     Document Type: Article

References (39)

1. Collins PL, Graham BS. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol. 2008;82(5):2040-2055.
2. Hall CB. The burgeoning burden of respiratory syncytial virus among children. Infect Disord Drug Targets. 2012;12(2):92-97.
3. Hall CB, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588-598.
4. Nair H, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and metaanalysis. Lancet. 2010;375(9725):1545-1555.
5. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol. 1969;89(4):435-448.
6. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol. 1969;89(4):405-421.
7. Kim HW, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89(4):422-434.
8. Cherukuri A, et al. An adjuvanted respiratory syncytial virus fusion protein induces protection in aged balb/c mice. Immun Ageing. 2012;9(1):21.
9. Smith G, et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One. 2012;7(11):e50852.
10. McLellan JS, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013;342(6158):592-598.
11. Beeler JA, van Wyke Coelingh K. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol. 1989;63(7):2941-2950.
12. Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3):531-537.
13. Meissner HC, Bocchini JA. Reducing RSV hospitalizations aap modifies recommendations for use of palivizumab in high-risk infants, young children. AAP News. 2009;30(7):1-1.
14. Wu H, Pfarr DS, Losonsky GA, Kiener PA. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol. 2008;317:103-123.
15. Arbiza J, et al. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol. 1992;73(pt 9):2225-2234.
16. López JA, et al. Antigenic structure of human respiratory syncytial virus fusion glycoprotein. J Virol. 1998;72(8):6922-6928.
17. McLellan JS, Chen M, Kim A, Yang Y, Graham BS, Kwong PD. Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat Struct Mol Biol. 2010;17(2):248-250.
18. Wu H, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol. 2007;368(3):652-665.
19. Toiron C, López JA, Rivas G, Andreu D, Melero JA, Bruix M. Conformational studies of a short linear peptide corresponding to a major conserved neutralizing epitope of human respiratory syncytial virus fusion glycoprotein. Biopolymers. 1996;39(4):537-548.
20. López JA, Andreu D, Carreño C, Whyte P, Taylor G, Melero JA. Conformational constraints of conserved neutralizing epitopes from a major antigenic area of human respiratory syncytial virus fusion glycoprotein. J Gen Virol. 1993;74(pt 12):2567-2577.
21. McLellan JS, et al. Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J Mol Biol. 2011;409(5):853-866.
22. Murata Y, Lightfoote PM, Rose RC, Walsh EE. Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus l1 capsomeres. Virol J. 2009;6:81.
23. Correia BE, et al. Proof of principle for epitope-focused vaccine design. Nature. 2014;507(7491):201-206.
24. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10(11):787-796.
25. Milich DR, Chen M, Schödel F, Peterson DL, Jones JE, Hughes JL. Role of B cells in antigen presentation of the hepatitis B core. Proc Natl Acad Sci U S A. 1997;94(26):14648-14653.
26. Lee BO, et al. Interaction of the hepatitis B core antigen and the innate immune system. J Immunol. 2009;182(11):6670-6681.
27. Conway JF, et al. Hepatitis B virus capsid: localization of the putative immunodominant loop (residues 78 to 83) on the capsid surface, and implications for the distinction between c and e-antigens. J Mol Biol. 1998;279(5):1111-1121.
28. Conway JF, Cheng N, Zlotnick A, Wingfield PT, Stahl SJ, Steven AC. Visualization of a 4-helix bundle in the hepatitis B virus capsid by cryo-electron microscopy. Nature. 1997;386(6620):91-94.
29. Whitacre DC, Lee BO, Milich DR. Use of hepadnavirus core proteins as vaccine platforms. Expert Rev Vaccines. 2009;8(11):1565-1573.
30. Wynne SA, Crowther RA, Leslie AG. The crystal structure of the human hepatitis B virus capsid. Mol Cell. 1999;3(6):771-780.
31. Billaud J, et al. Advantages to the use of rodent hepadnavirus core proteins as vaccine platforms. Vaccine. 2007;25(9):1593-1606.
32. Billaud J, et al. Combinatorial approach to hepadnavirus-like particle vaccine design. J Virol. 2005;79(21):13656-13666.
33. Walsh EE, Falsey AR. Age related differences in humoral immune response to respiratory syncytial virus infection in adults. J Med Virol. 2004;73(2):295-299.
34. Graham BS. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev. 2011;239(1):149-166.
35. Delgado MF, et al. Lack of antibody affinity maturation due to poor toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med. 2009;15(1):34-41.
36. Milich DR, Schödel F, Hughes JL, Jones JE, Peterson DL. The hepatitis B virus core and e antigens elicit different TH cell subsets: antigen structure can affect TH cell phenotype. J Virol. 1997;71(3):2192-2201.
37. Eschli B, et al. Early antibodies specific for the neutralizing epitope on the receptor binding subunit of the lymphocytic choriomeningitis virus glycoprotein fail to neutralize the virus. J Virol. 2007;81(21):11650-11657.
38. McLellan JS, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusionspecific neutralizing antibody. Science. 2013;340(6136):1113-1117.
39. Coler RN, et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One. 2011;6(1):e16333.